Skip to main content

NanoSTARS imaging for STEM cell therapy for arthritic joints

Objective

STARSTEM proposes imaging of stem cell engraftment in arthritic joints of large animals at clinically relevant depths, using nanoparticles with novel optical properties which enable unprecedented penetration depth and sensitivity. Arthritis is the most prevalent disease worldwide, with osteoarthritis (OA) affecting around 10% of the global population and around 70 million patients in Europe. There is no effective cure for OA at present and the majority of the treatments are symptomatic and not restorative. Stem cell therapy provides a unique opportunity for the self-regeneration of injured cartilage. One of the major hurdles in stem cell mediated-therapy is the inability to diagnose successful engraftment in real time using conventional imaging techniques. STARSTEM will address the major technology gaps to enable imaging of human stem cells at clinically relevant depths. STARSTEM is proposing the use of novel dual plasmonic gold nanostars (nanostars)-enhanced multi-modal imaging to detect stem cell engraftment and tissue repair, and thus their activity and efficacy as a therapy. STARSTEM will harness the best properties of light and sound with a photoacoustic (PA) imaging system for large animal and human finger imaging as proof-of-concept which exploits the unique advantages of our nanomaterial for differential and deep-tissue imaging. Functional imaging using PA enables the real time monitoring of engraftment and the therapeutic process at the site of interest, while highly sensitive anatomical imaging using MRI (using nanostar conjugated with magnetic nanoparticles as contrast agent) enables tracking of the movement and retention in individual organs of the transplanted cells that did not engraft. Algorithms for co-registered PA-MRI imaging approach will enable monitoring of the therapeutic process with high sensitivity. The overall imaging approach is designed to address small to large animal testing for efficacy and safety prior to clinical testing on humans.

Call for proposal

H2020-NMBP-2017-two-stage
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

NATIONAL UNIVERSITY OF IRELAND GALWAY
Address
University Road
H91 Galway
Ireland
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 989 565

Participants (8)

TECHNISCHE UNIVERSITAET MUENCHEN
Germany
EU contribution
€ 599 260
Address
Arcisstrasse 21
80333 Muenchen
Activity type
Higher or Secondary Education Establishments
UNIVERSITA DEGLI STUDI DI GENOVA
Italy
EU contribution
€ 1 014 560,99
Address
Via Balbi 5
16126 Genova
Activity type
Higher or Secondary Education Establishments
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
EU contribution
€ 778 101,25
Address
Trinity Lane The Old Schools
CB2 1TN Cambridge
Activity type
Higher or Secondary Education Establishments
FUNDACIO INSTITUT DE CIENCIES FOTONIQUES
Spain
EU contribution
€ 506 840
Address
Avinguda Carl Friedrich Gauss 3
08860 Castelldefels
Activity type
Research Organisations
ITHERA MEDICAL GMBH
Germany
EU contribution
€ 535 625
Address
Zielstattstrasse 13
81379 Munchen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
PINTAIL LTD
Ireland
EU contribution
€ 250 000
Address
Springhill Avenue 77
A94 K542 Blackrock
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
BIORIGEN SRL

Participation ended

Italy
EU contribution
€ 0
Address
Via De Marini 1 7Th Floor
16149 Genova
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ITHERA SCIENTIFIC GMBH
Germany
EU contribution
€ 260 000
Address
Zielstattstrasse 13
81379 Munchen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)